

Invega Sustenna® Review

1. You are preparing to administer Invega Sustenna® to a patient who weighs ^{66.4kg} 146 pounds. What size needle will you use? pts > 90kg = 1 1/2 inch 22G (deltoid)
pts weighing < 90 kg, use a 1-inch 23G needle (deltoid) or 1 1/2 inch 22G needle regardless of age (gluteal)
2. Name the most common side effects a patient may experience when taking Invega Sustenna®.
injection site reactions, somnolence/sedation, dizziness, akathisia, + EPS

3. What black box warning is associated with this medication?
↑ mortality in elderly pts with dementia-related psychosis (NOT approved for these pts)
4. What are the standard *recommended* Day 1 and Day 8 initiation dosages for a person with schizophrenia?
day 1 (deltoid): 234mg day 8 (deltoid): 156mg
5. What is the standard *recommended* maintenance dosage for a patient with schizophrenia?
monthly maintenance dose (deltoid + gluteal) 39-234mg^b b = 117mg, but some pts benefit from ↑ or ↓ doses
6. What is the *correct* location for administration of the Day 1 and Day 8 initiation doses?
IM injection ONLY! day 1 + 8 = deltoid
7. What are the *recommended* Day 1 and Day 8 initiation dosages for a person with a creatinine clearance of 65mL/min?
≥ 50, but < 80 mL/min (mild renal impairment) day 1: 156mg day 8: 117mg (both in deltoid)

8. What would the *recommended* maintenance dosage be for a patient with mild renal impairment?

78 mg into deltoid or gluteal

9. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®?

paliperidone is a major active metabolite of risperidone + doing a test trial predicts pt's likely outcome to Invega. This also gives pt's body a chance to assess tolerance.

10. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure.

1. shake syringe vigorously for a minimum of 10 seconds to ensure homogeneous suspension.
 2. peel safety needle pouch halfway open. grasp needle shaft using plastic peel pouch + attach safety needle.
 3. pull needle straight up. DO NOT TWIST the sheath bc needle may loosen from syringe.
-

11. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration.

A common side effect is EPS, which is a group of disorders: some reversible, irreversible, or have long-term consequences.
